Related Experiment Video
Updated: Jul 17, 2025
Experimental Metastasis Assay
Published on: August 24, 2010
Microsomal glutathione transferase 1 controls metastasis and therapeutic response in melanoma
Jie Zhang1, Zhi-Wei Ye1, Paramita Chakraborty2
1Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, United States.
Abstract:
While recent targeted and immunotherapies in malignant melanoma are encouraging, most patients acquire resistance, implicating a need to identify additional drug targets to improve outcomes. Recently, attention has been given to pathways that regulate redox homeostasis, especially the lipid peroxidase pathway that protects cells against ferroptosis. Here we identify microsomal glutathione S-transferase 1 (MGST1), a non-selenium-dependent glutathione peroxidase, as highly expressed in malignant and drug resistant melanomas and as a specific determinant of metastatic spread and therapeutic sensitivity. Loss of MGST1 in mouse and human melanoma enhanced cellular oxidative stress, and diminished glycolysis, oxidative phosphorylation, and pentose phosphate pathway. Gp100 activated pmel-1 T cells killed more Mgst1 KD than control melanoma cells and KD cells were more sensitive to cytotoxic anticancer drugs and ferroptotic cell death. When compared to control, mice bearing Mgst1 KD B16 tumors had more CD8+ T cell infiltration with reduced expression of inhibitory receptors and increased cytokine response, large reduction of lung metastases and enhanced survival. Targeting MGST1 alters the redox balance and limits metastases in melanoma, enhancing the therapeutic index for chemo- and immunotherapies.
Insights
Microsomal glutathione S-transferase 1 (MGST1) is a novel drug target in melanoma. Inhibiting MGST1 reduces metastasis and enhances sensitivity to chemotherapy and immunotherapy in malignant melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Malignant melanoma therapies face challenges due to acquired drug resistance.
- Redox homeostasis pathways, particularly those protecting against ferroptosis, are critical in cancer.
- Microsomal glutathione S-transferase 1 (MGST1) is a glutathione peroxidase involved in cellular protection.
Purpose of the Study:
- To identify novel drug targets for malignant melanoma, addressing therapeutic resistance.
- To investigate the role of MGST1 in melanoma progression, metastasis, and therapeutic sensitivity.
Main Methods:
- Expression analysis of MGST1 in malignant and drug-resistant melanoma.
- Functional studies involving MGST1 knockdown (KD) in mouse and human melanoma models.
- Assessment of cellular metabolism, oxidative stress, immune cell infiltration, and metastatic spread in Mgst1 KD models.
- Evaluation of sensitivity to chemotherapy, immunotherapy, and ferroptosis in Mgst1 KD cells.
Main Results:
- MGST1 is highly expressed in malignant and drug-resistant melanomas.
- Loss of MGST1 leads to increased oxidative stress, altered cellular metabolism, and enhanced sensitivity to anticancer drugs and ferroptosis.
- Mgst1 KD B16 tumors exhibited increased CD8+ T cell infiltration, reduced lung metastases, and improved survival in mice.
- Targeting MGST1 enhances the therapeutic index of chemo- and immunotherapies.
Conclusions:
- MGST1 is a key determinant of melanoma metastasis and therapeutic sensitivity.
- Targeting MGST1 represents a promising strategy to overcome drug resistance and limit melanoma spread.
- Modulating MGST1 can enhance the efficacy of existing melanoma treatments.
Related Concept Videos
01:22Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...